Omeros Corporation Aktie News

Omeros-Aktie schoss am Donnerstag auf ein Fünf-Jahres-Hoch nach herausragenden Ergebnissen für das zweite Quartal seines neuen Behandlungsverfahrens für Transplantationskomplikationen.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) gab heute jüngste Highlights und Entwicklungen sowie die Finanzergebnisse für das zweite Quartal zum 30. Juni 2026 bekannt, die Folgendes umfassen: Zweites Quartal und jüngste Highlights YARTEMLEA®, die erste und einzige zugelassene Behandlung für stem cell transplant-associated thrombotic microangiopathy (TA-TMA), eine oft tödliche Ko...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) gab heute bekannt, dass die Centers for Medicare & Medicaid Services (CMS) YARTEMLEA® (narsoplimab-wuug) im Rahmen der Final Rule zum Hospital Inpatient Prospective Payment System (IPPS) für das Geschäftsjahr (FY) 2027 den Status New Technology Add-On Payment (NTAP) zuerkannt haben. Ab dem 1. Oktober 2026 werden berechtigte Krankenhäus...

Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Medicines Agency's (EMA) expert panel has rejected its primary commercial asset.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Following an oral ...

Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction o...